Howell Jessica A, Khan Shahid A
Department of Hepatology, Level 10 QEQM Building, St Mary's Hospital Campus, Imperial College London, Praed Street, London, W2 1NY, UK.
Department of Medicine, St Vincent's Hospital, University of Melbourne, Victoria Pde, Fitzroy 3065, Victoria, Australia.
Hepat Oncol. 2016 Apr;3(2):167-180. doi: 10.2217/hep-2015-0003. Epub 2016 Mar 29.
Cholangiocarcinoma (CCA) is a devastating malignancy with high mortality, in part due to the combination of late presentation, significant diagnostic challenges and limited effective treatment options. Late presentation and diagnosis contribute to the high mortality in CCA and there is an urgent unmet need for diagnostic and prognostic biomarkers to facilitate early diagnosis and treatment stratification to improve clinical outcomes. MiRs are small ncRNA molecules that regulate gene expression and modulate both tumor suppressive and oncogenic pathways. They have a well-defined role in carcinogenesis, including CCA. In this review, we outline the evidence for MiRs in the pathogenesis of CCA and their potential utility as diagnostic and prognostic biomarkers to guide clinical management.
胆管癌(CCA)是一种具有高死亡率的毁灭性恶性肿瘤,部分原因是出现较晚、诊断面临重大挑战以及有效的治疗选择有限。出现较晚和诊断延迟导致了CCA的高死亡率,因此迫切需要诊断和预后生物标志物来促进早期诊断和治疗分层,以改善临床结果。微小RNA(miRs)是调节基因表达并调控肿瘤抑制和致癌途径的小非编码RNA分子。它们在包括CCA在内的肿瘤发生中具有明确的作用。在本综述中,我们概述了miRs在CCA发病机制中的证据及其作为诊断和预后生物标志物指导临床管理的潜在用途。